Aster DM Quality

Q1 FY27Healthcare Services

Aster DM Quality Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹766

Market cap₹66.4K Cr

P/E183.9

Updated25 Aug 2026

Read5 min read

What the Q1 FY27 call signalled

3 of 3 strong

RevenueRank 2

MarginRank 1

CapexYes

Not discussed on this call: fundraise, order book.

The short version

Revenue growth driven by higher patient volumes and increased realizations due to complex case mix. EBITDA margin target of 24%-25% expected within 2-3 years post-merger, with a good exit from FY27 and reaching targets between FY28-FY29.

From Aster DM Quality's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 2

Revenue growth driven by higher patient volumes and increased realizations due to complex case mix.
Over 2 million patients treated in Q1, up 13% YoY; blended occupancy increased by 510 bps to 64%.
Mature Units (73% revenue) grew 19% YoY; Focus Units (15% revenue) grew 16% YoY; Emerging Units grew 63% YoY.
Emerging hospitals like Kasaragod achieved fast ramp-up, reaching EBITDA breakeven in 9 months.
Organic growth target: 5%-6% volume growth and 7%-8% ARPP growth.
Medical Value Travel (MVT) revenue growing 62% YoY; management aims to grow MVT faster than overall business, targeting mid to double-digit share in revenue.
Capacity expansion of over 4,170 beds planned in next 3-4 years, focusing 53% on brownfield projects for faster ramp-ups.
Sustained double-digit volume growth expected across core and emerging markets with a focus on specialty programs and clinical excellence.

Profitability & Margins

- EBITDA margin target of 24%-25% expected within 2-3 years post-merger, with a good exit from FY27 and reaching targets between FY28-FY29. - Synergies targeted to contribute 10%-15% of FY24 proforma EBITDA incrementally, with significant realization expected starting FY27 onwards. - Revenue growth driven by volume expansion, enriched case mix, and higher ARPP, with mature units growing 19% YoY and emerging units showing 63% revenue growth. - EBITDA expected to grow through operational leverage, cost efficiencies, and scale, with emerging units’ EBITDA margin expanding to 12.4%. - Medical Value Travel (MVT) business targeted to grow over 50% CAGR, moving from low single digits to mid-single and then double-digit contribution over time. - Strong clinical platform and brownfield expansion pipeline to sustain growth momentum, with over 4,170 beds addition planned in next 3-4 years. Overall, the company is confident of delivering long-term value with robust operating earnings growth and margin expansion.

See what Aster DM Quality said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Bhubaneswar project is on the radar for expansion.
New cancer center inauguration planned in Raipur by mid-August 2026.
Capacity additions planned in 2028 at Kottayam and Nagercoil (bed additions ongoing).
Bed additions also happening at Banjara Hills, Nampally, and Shifa by 2028.
Greenfield projects include Trivandrum hospital expected operational by H2 FY27 (~January 2027).
Hyderabad hospital in interior work phase; planned operationalization by April 2027 (FY28 start).
Sarjapur project (~450 beds, two blocks) work already started on Block 1 focused on MEP and interiors.
Annual bed capacity increase and expansions, both brownfield and greenfield, are actively being pursued with detailed updates to be shared.
Oncology investments targeting Tier 2 and Tier 3 cities as a strategic growth area requiring deep pockets.
Continuous investments in talent, technology, and infrastructure highlighted as ongoing priorities.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹654 Cr

Rev 2Mar 2

4₹1.3L Cr

Rev 2Mar 3

5₹94.4K Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript provided from the Q1FY27 earnings call of Aster DM Quality Care Limited does not mention any current or planned fundraising through debt or equity.
The focus appears to be on operational growth, hospital expansion, synergy realization, and margin improvement.
Management emphasizes strong internal cash flows and growth from existing operations rather than raising external funds.
There is no explicit discussion or indication about future debt or equity fundraising plans during this call.
Any detailed capital raise plans might be handled offline or disclosed separately outside this call transcript.

See what Aster DM Quality said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the Aster DM Quality Care Limited Q1 FY27 Earnings Conference Call does not explicitly mention the current or expected order book or pending orders. The discussion primarily focuses on: - EBITDA performance and hospital maturity categories. - Expansion plans including bed additions and new hospital projects (e.g., Bhubaneswar, Raipur cancer center, Kottayam, Nagercoil, Banjara Hills). - Financial performance highlights including revenue and EBITDA growth. - Strategy on clinical programs and geographical focus. - Brownfield and greenfield capacity additions totaling over 4,170 beds planned over the next 3-4 years. No specific data or figures related to order book or pending orders are provided in the available transcript pages. If you need detailed order book insights, it may require direct data from company financial disclosures or specific management commentary.

Aster DM Quality — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹154 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Aster DM Quality Care Ltd's management said in earlier quarters

Others in Healthcare Services this season

Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aster DM Quality Q1 FY27 results?

What is Aster DM Quality share price analysis?

Aster DM Quality currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 183.9 with a market cap of ₹66,382 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aster DM Quality planning capital expenditure?

Bhubaneswar project is on the radar for expansion. - New cancer center inauguration planned in Raipur by mid-August 2026. - Capacity additions planned in 2028 at Kottayam and Nagercoil (bed additions ongoing). - Bed additions also happening at Banjara Hills, Nampally, and Shifa by 2028. - Greenfield projects include Trivandrum hospital expected operational by H2 FY27 (~January 2027). - Hyderabad hospital in interior work phase; planned operationalization by April 2027 (FY28 start). - Sarjapur project (~450 beds, two blocks) work already started on Block 1 focused on MEP and interiors.

Keep Aster DM Quality on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.